Semaglutide in NASH-related cirrhosis: still a long way to go?

We read with interest Rohit Loomba and colleagues' Article1 in The Lancet Gastroenterology & Hepatology on a phase 2 randomised controlled trial to assess the efficacy and safety of semaglutide in patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis. Semaglutide 2·4 mg once weekly did not improve fibrosis or lead to NASH resolution; however, it was associated with improvements in cardiometabolic parameters (weight loss, dyslipidaemia, and glycaemic control) and reduction in liver fat on imaging.